Patent · US Active

Single high dose of MVA induces a protective immune response in neonates and infants

US9707291B2 · kind B2 · utility

0Cited by

33References

22Claims

0Family size

Assignee

Bavarian Nordic A/S · DK

Inventors

Cédric Cheminay · Munich, DE
Ariane Volkmann · Andechs, DE
Paul Chaplin · Munich, DE
Mark Suter · Luzern, CH

Key dates

Filing date	Mar 14, 2014
Grant date	Jul 18, 2017
Priority date	—
Expiry date	Mar 14, 2034

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to compositions and methods for inducing a protective immune response against a poxvirus in a human neonate or infant of less than 6 months of age. The invention encompasses administering a single high dose of an MVA to a human neonate or infant of less than 6 months of age, wherein the administration induces protective T- and B-cell responses against a poxvirus in the human neonate or infant.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.